What happened with BGM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
BGM Group Ltd.’s largest business makes medicines and pharmaceutical ingredients, including oxytetracycline products sold by Gansu QLS under the Qilian Shan brand. Pharmaceutical companies use its ingredients to make medicines, while distributors, dealers and corporate customers buy its finished products. The business also sells licorice and heparin products, sausage casings and fertilizer. A few large customers account for a significant share of product sales, and those relationships rely on repeat business rather than long-term supply contracts. Pharmaceutical operations require licenses and permits that must be maintained.
Insurance is its other substantial source of revenue: insurers pay commissions and fees when customers purchase policies. This income depends on policy sales and the rates insurers pay, which regulation can constrain. BGM also earns a smaller share of revenue from AI solutions. Through Du Xiao Bao and Bao Wang, it provides insurers, insurance brokers and consumers with services supporting sales, underwriting, claims and customer service.
BGM itself is a Cayman Islands holding company with no operations of its own. Its China business depends on contracts that let it direct Gansu QLS and receive its economic benefits, rather than ownership of that company’s equity. The holding company relies principally on dividends from its Chinese subsidiary for cash. Chinese rules restrict profit distributions and cross-border transfers, and the business depends on the contractual structure remaining valid and enforceable.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
These peers cover BGM's pharmaceutical business, but its results increasingly depend on Chinese insurance distribution and demand for insurance-focused AI services, which together generated 38% of fiscal 2025 revenue.
Zhengye Biotechnology and BGM both depend on animal-health spending in China: Zhengye sells livestock vaccines, while BGM sells veterinary oxytetracycline medicines. Zhengye's livestock-vaccine sales offer a read on spending to prevent animal diseases, rather than demand for BGM's treatments directly.
China Pharma and BGM compete in China's market for human infection and respiratory medicines, selling through licensed pharmaceutical distributors that supply hospitals and pharmacies. Watch China Pharma's antiviral, infection and respiratory revenue for a read on the medicine categories that overlap with BGM.
Universe Pharmaceuticals and BGM compete for sales through China's pharmaceutical distribution market, both making Chinese medicines that include treatments for respiratory symptoms. Universe's cold-and-flu medicine sales are the part to watch for demand closest to BGM's respiratory products.
China SXT competes with BGM's licorice and Chinese medicine products for traditional-medicine spending through Chinese drug stores, selling prepared medicinal pieces to hospitals and stores. Watch sales of its products taken directly or after soaking in hot water: they offer a different way to make Chinese medicines easier to take than BGM's slow-dissolving Gan Di Xin.
No upcoming items to show.
Earnings, filings and other dated events show up here once their dates are set.
